Utilizing the lamb model to evaluate the efficacy of inhaled therapeutics in collaboration with pharmaceutical companies, this work was recently published in Advanced Science. The data obtained from the lamb model have enriched our understanding of the mechanisms, pharmacokinetics, and effects of inhaled treatment for RSV infection. Notably, the treatment proved effective even after the RSV infection had been established in lambs. Inhaled “Muco-Trapping” Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections".

Utilizing a lamb model to evaluate oral therapeutics targeting RSV, multiple RSV targets have been tested in lambs, including the RSV polymerase. This work was recently published in the Journal of Medicinal Chemistry under the title, "Discovery of gem-Dimethyl-hydroxymethylpyridine Derivatives as Potent Non-nucleoside RSV Polymerase Inhibitors."

HMPV

 

With over a decade of experience in RSV research and more than six years at Lambcure LLC, a pioneering biomedical research company, we are now breaking new ground in Human Metapneumovirus (HMPV) research. Over the past few years, our dedicated team has partnered with leading academic institutions and pharmaceutical companies to develop an innovative lamb model for HMPV.

We have conducted numerous trials to validate our hypotheses and are actively pursuing several grants to support the continued development of this model. As we advance this promising area of research, we are keen to collaborate with scientists in the field and companies interested in joining us to further refine and expand the HMPV lamb model.

Building on our proven success with RSV, we are confident that this venture will yield impactful results.

For more detailed information about our work on HMPV, please do not hesitate to contact us.